Ervaxx pursues non-peptide tumor antigens via Cardiff University TCR, T cell deal

A research collaboration with Cardiff University will enable Ervaxx to go beyond targeting neoantigens derived from typically unexpressed DNA, to tumor antigens that aren’t peptides.

Ervaxx Ltd. will fund research, conducted in the lab of SAB member Andrew Sewell, to discover and characterize T cells and TCRs against neoantigens discovered via its Dark Antigens platform as well as other cancer antigens. ...